ArticlePharmaceutics2020
Hybrid Pectin-Liposome Formulation against Multi-Resistant Bacterial Strains.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Review
- Liposomal Fluopsin C: Physicochemical Properties, Cytotoxicity, and Antibacterial Activity In Vitro and over In Vivo MDRAntibiotics (Basel, Switzerland) · 2025Article
- Lipid Nanoparticles Carrying Essential Oils for Multiple Applications as Antimicrobials.Pharmaceutics · 2025Review
- Antimicrobial Activity of Essential-Oil-Based Nanostructured Lipid Carriers againstPharmaceutics · 2024Article
- A new standardization for the use of chicken embryo: selection of target from the phage display library and infection.Applied microbiology and biotechnology · 2024Article
- Liposome-Based Antibacterial Delivery: An Emergent Approach to Combat Bacterial Infections.ACS omega · 2023Review
- Coating Materials to Increase the Stability of Liposomes.Polymers · 2023Review
- Oleogel-based drug delivery for the treatment of periodontitis: current strategies and future perspectives.F1000Research · 2023Review
- Lipid nanoparticles based on natural matrices with activity against multidrug resistant bacterial species.Frontiers in cellular and infection microbiology · 2023Article
- Lipid-Based Drug Delivery Systems for Diseases Managements.Biomedicines · 2022Review
- Physiological Changes in Chicken Embryos Inoculated with Drugs and Viruses Highlight the Need for More Standardization of this Animal Model.Animals : an open access journal from MDPI · 2022Article
- Hybrid Nanobeads for Oral Indomethacin Delivery.Pharmaceutics · 2022Article
- Bacteriomimetic Liposomes Improve Antibiotic Activity of a Novel Energy-Coupling Factor Transporter Inhibitor.Pharmaceutics · 2021Article
- Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance.Molecules (Basel, Switzerland) · 2021Review
- The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic.Future microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This work describes the development of a gastroresistant antimicrobial formulation composed of two carriers, pectin and liposomes, intended to improve the efficiency of norfloxacin (NOR) against multi-resistant bacterial strains. The formulations showed physicochemical stability for 180 days (4 °C) in terms of size, polydispersity, and zeta potential of the vesicles, prolonging the in vitro release of NOR for 11 h. The hybrid nanocarriers improved the in vitro antimicrobial activity against different multidrug-resistant bacterial strains, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.